as 05-30-2025 4:00pm EST
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
Founded: | 2010 | Country: | United States |
Employees: | N/A | City: | FLORHAM PARK |
Market Cap: | 67.3M | IPO Year: | 2017 |
Target Price: | N/A | AVG Volume (30 days): | 20.0K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.09 | EPS Growth: | N/A |
52 Week Low/High: | $0.98 - $2.97 | Next Earning Date: | 05-12-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
BYSI Breaking Stock News: Dive into BYSI Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Simply Wall St.
17 days ago
GlobeNewswire
19 days ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
4 months ago
GlobeNewswire
4 months ago
GlobeNewswire
7 months ago
The information presented on this page, "BYSI BeyondSpring Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.